0001178913-23-000242.txt : 20230124 0001178913-23-000242.hdr.sgml : 20230124 20230124102100 ACCESSION NUMBER: 0001178913-23-000242 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230119 FILED AS OF DATE: 20230124 DATE AS OF CHANGE: 20230124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: aMoon Growth Fund Limited Partnership CENTRAL INDEX KEY: 0001744099 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39279 FILM NUMBER: 23546232 BUSINESS ADDRESS: STREET 1: 34 YERUSHALAYIM RD. CITY: RAANANA STATE: L3 ZIP: 4350110 BUSINESS PHONE: 972(73)3989560 MAIL ADDRESS: STREET 1: 34 YERUSHALAYIM RD. CITY: RAANANA STATE: L3 ZIP: 4350110 FORMER NAME: FORMER CONFORMED NAME: aMoon 2 Fund Limited Partnership DATE OF NAME CHANGE: 20180620 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schindel Yair Chaim CENTRAL INDEX KEY: 0001823758 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39279 FILM NUMBER: 23546231 MAIL ADDRESS: STREET 1: YERUSHALAYIM ROAD 34 STREET 2: BEIT GAMLA ENTRANCE B CITY: RA'ANANA STATE: L3 ZIP: 4350110 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Old Ayala, Inc CENTRAL INDEX KEY: 0001797336 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 823578375 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1313 N. MARKET STREET STREET 2: SUITE 5100 CITY: WILMINGTON STATE: DE ZIP: 19801 BUSINESS PHONE: (857) 444-0553 MAIL ADDRESS: STREET 1: 1313 N. MARKET STREET STREET 2: SUITE 5100 CITY: WILMINGTON STATE: DE ZIP: 19801 FORMER COMPANY: FORMER CONFORMED NAME: Ayala Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20191218 4 1 zk2329064.xml X0306 4 2023-01-19 1 0001797336 Old Ayala, Inc AYLA 0001744099 aMoon Growth Fund Limited Partnership 34 YERUSHALAIM ROAD BEIT GAMLA, 6TH FLOOR RAANANA L3 4350110 ISRAEL 0 0 1 0 0001823758 Schindel Yair Chaim 34 YERUSHALAIM ROAD BEIT GAMLA, 6TH FLOOR RAANANA L3 4350110 ISRAEL 0 0 0 1 shareholder of 10% holder Common Stock 2023-01-19 4 D 0 2991473 D 0 D This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, upon the consummation of the merger on January 19, 2023, each share of Ayala's common stock was cancelled and converted into the right to receive shares of Advaxis common stock based on the exchange ratio set forth therein. The reported shares were held of record by aMoon Growth Fund Limited Partnership ("aMoon Growth Fund"). aMoon Growth Fund G.P. Limited Partnership ("aMoon Growth Fund G.P.") is the sole General Partner of aMoon Growth Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon Growth Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel may have been deemed to have shared voting and investment power with respect to the shares held of record by aMoon Growth Fund. Each of aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Growth Fund except to the extent of its or his pecuniary interest therein, if any. /s/ Yair Schindel, the sole shareholder of aMoon General Partner Ltd., the sole General Partner of aMoon Growth Fund G.P. Limited Partnership, the sole General Partner of aMoon Growth Fund, Limited Partnership 2023-01-24 /s/ Yair Schindel 2023-01-24